Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalfurafine Hydrochloride for Pruritus in Hemodialysis Patients
NCT07650851Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of nalfurafine in chronic kidney disease (CKD) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Visual Analogue Scale at 12 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
nalfurafine
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07650851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650851.